12:00 AM
May 31, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Provecta: Additional Phase II data

Additional data from the open-label, U.S. and Australian Phase II PV-10-MM-02 trial in 40 evaluable patients with stage III or IV melanoma showed that intralesional PV-10 produced an ORR of 61%, with 33% of patients achieving a complete response, 28% a partial response and 18% achieving stable disease of their target lesions at...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >